Overview and Benefits of Port Delivery System with Ranibizumab

Author(s):

Aleksandra Rachitskaya, MD,Jordan Graff, MD, FACS

Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.

EP: 1.Overview of Novel Treatments for Retinal Vascular Diseases

Now Viewing

EP: 2.Overview and Benefits of Port Delivery System with Ranibizumab

EP: 3.Patient Selection for Port Delivery System

EP: 4.Considerations for Surgical Implant of the Port Delivery System and Refill Process

EP: 5.Key Steps in the Surgical Implantation of the Port Delivery System

EP: 6.Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System

EP: 7.Adverse Events of the Port Delivery System and Addressing Challenges With Adoption

EP: 8.Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

Video content above is prompted by the following:

Can you provide an overview of the port delivery device with ranibizumab approved for treating neovascular AMD?
How does the device function?
What are the benefits of using the port delivery device with ranibizumab?
Certainty of 6 months of continuous anti-VEGF delivery
Patients in clinical trials prefer PDS over intravitreal injections

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!